Literature DB >> 18324334

Substance abuse in patients with attention-deficit/hyperactivity disorder.

Oscar Bukstein1.   

Abstract

Substance use disorder (SUD) is a common comorbidity of attention-deficit/hyperactivity disorder (ADHD) that is frequently seen during adolescence. Physicians who treat patients with ADHD need to be aware of both the behavioral and medical signs of substance abuse and closely screen their patients for SUD. Optimal treatment of the symptoms of ADHD is the most effective way to reduce the incidence of SUD, but the use of stimulants, the first-line therapy for ADHD, is associated with an appreciable degree of abuse and misuse of therapeutic drugs. Cardiovascular and psychiatric risks with ADHD drugs have resulted in recent labeling changes for these drugs. A correct diagnosis of ADHD is important in validating the use of stimulant medication. New strategies for effectively treating ADHD that may minimize the risk for drug abuse are being developed and include extended-release formulations of currently used drugs, new nonstimulant drugs for the treatment of ADHD, and novel prodrugs that optimize therapeutic plasma concentrations of drugs. Nonmedication or psychosocial treatments, especially for adult ADHD, are also available. Further assessment of these strategies should permit the development of new approaches to the treatment of ADHD that reduce the risk for abuse and misuse of stimulant medications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324334      PMCID: PMC2258479     

Source DB:  PubMed          Journal:  Medscape J Med        ISSN: 1934-1997


  27 in total

Review 1.  Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability.

Authors:  R Andrew Chambers; Jane R Taylor; Marc N Potenza
Journal:  Am J Psychiatry       Date:  2003-06       Impact factor: 18.112

2.  Validity of the CRAFFT substance abuse screening test among adolescent clinic patients.

Authors:  John R Knight; Lon Sherritt; Lydia A Shrier; Sion Kim Harris; Grace Chang
Journal:  Arch Pediatr Adolesc Med       Date:  2002-06

3.  A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients.

Authors:  S D Passik; K L Kirsh; M V McDonald; S Ahn; S M Russak; L Martin; B Rosenfeld; W S Breitbart; R K Portenoy
Journal:  J Pain Symptom Manage       Date:  2000-04       Impact factor: 3.612

4.  Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

5.  Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder.

Authors:  Joseph Biederman; Declan Quinn; Margaret Weiss; Sabri Markabi; Meredith Weidenman; Kathryn Edson; Goeril Karlsson; Harald Pohlmann; Sharon Wigal
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD.

Authors:  Brooke S G Molina; William E Pelham
Journal:  J Abnorm Psychol       Date:  2003-08

7.  The RAFFT as a screening tool for adult substance use disorders.

Authors:  Leo Bastiaens; Kathleen Riccardi; Duru Sakhrani
Journal:  Am J Drug Alcohol Abuse       Date:  2002-11       Impact factor: 3.829

Review 8.  Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder.

Authors:  Lenard Adler; Julie Cohen
Journal:  Psychiatr Clin North Am       Date:  2004-06

9.  Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study.

Authors:  Joseph Biederman; Samuel W Boellner; Ann Childress; Frank A Lopez; Suma Krishnan; Yuxin Zhang
Journal:  Biol Psychiatry       Date:  2007-07-12       Impact factor: 13.382

10.  Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature.

Authors:  Timothy E Wilens; Stephen V Faraone; Joseph Biederman; Samantha Gunawardene
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

View more
  5 in total

Review 1.  Screening and brief intervention for underage drinkers.

Authors:  Duncan B Clark; Adam J Gordon; Lorraine R Ettaro; Jill M Owens; Howard B Moss
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

2.  From the black widow spider to human behavior: Latrophilins, a relatively unknown class of G protein-coupled receptors, are implicated in psychiatric disorders.

Authors:  Ariel F Martinez; Maximilian Muenke; Mauricio Arcos-Burgos
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-11-12       Impact factor: 3.568

3.  Prenatal Stress Alters Progestogens to Mediate Susceptibility to Sex-Typical, Stress-Sensitive Disorders, such as Drug Abuse: A Review.

Authors:  Cheryl A Frye; Jason J Paris; Danielle M Osborne; Joannalee C Campbell; Tod E Kippin
Journal:  Front Psychiatry       Date:  2011-10-17       Impact factor: 4.157

Review 4.  A common genetic network underlies substance use disorders and disruptive or externalizing disorders.

Authors:  Mauricio Arcos-Burgos; Jorge I Vélez; Benjamin D Solomon; Maximilian Muenke
Journal:  Hum Genet       Date:  2012-04-11       Impact factor: 4.132

5.  Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Authors:  Jan K Buitelaar; J Antoni Ramos-Quiroga; Miguel Casas; J J Sandra Kooij; Asko Niemelä; Eric Konofal; Joachim Dejonckheere; Bradford H Challis; Rossella Medori
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.